VESELKA, Josef, Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA, Maksim KASHTANOV, Maciej DABROWSKI, Peter Riis HANSEN, Hubert SEGGEWISS, Jiri BONAVENTURA, Eva POLAKOVA, Eva HANSVENCLOVA, Henning BUNDGAARD, Jurrien TEN BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ and Morten Kvistholm JENSEN. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. International Journal of Cardiology. Clare: Elsevier Ireland Ltd., 2021, vol. 333, June 2021, p. 127-132. ISSN 0167-5273. Available from: https://dx.doi.org/10.1016/j.ijcard.2021.02.056.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy
Authors VESELKA, Josef (203 Czech Republic, guarantor), Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA (203 Czech Republic), Maksim KASHTANOV, Maciej DABROWSKI, Peter Riis HANSEN, Hubert SEGGEWISS, Jiri BONAVENTURA (203 Czech Republic), Eva POLAKOVA (203 Czech Republic), Eva HANSVENCLOVA (203 Czech Republic), Henning BUNDGAARD, Jurrien TEN BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Morten Kvistholm JENSEN.
Edition International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2021, 0167-5273.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.039
RIV identification code RIV/00216224:14110/21:00123837
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ijcard.2021.02.056
UT WoS 000730511500028
Keywords in English Alcohol septal ablation; Hypertrophic cardiomyopathy; Alcohol dose
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/7/2023 12:58.
Abstract
Background: The aim of this study was to evaluate short-and long-term outcomes related to dose of alcohol administered during alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM). Current guidelines recommend using 1-3 mL of alcohol administered in the target septal perforator artery, but this recommendation is based more on practical experience of interventionalists rather than on systematic evidence. Methods: We included 1448 patients and used propensity score to match patients who received a low-dose (1.0-1.9 mL) versus a high-dose (2.0-3.8 mL) of alcohol during ASA. Results: The matched cohort analysis comprised 770 patients (n = 385 in both groups). There was a similar occurrence of 30-day post-procedural adverse events (13% vs. 12%; p = 0.59), and similar all-cause mortality rates (0.8% vs. 0.5%; p = 1) in the low-dose group and the high-dose group, respectively. In the long-term follow-up (5.4 +/- 4.5 years), a total of 110 (14%) patients died representing 2.58 deaths and 2.64 deaths per 100 patient years in the low dose and the high dose group (logrank, p = 0.92), respectively. There were no significant differences in the long-term dyspnea and left ventricular outflow gradient between the two groups. Patients treated with a low-dose of alcohol underwent more subsequent septal reduction procedures (logrank, p = 0.04). Conclusions: Matched HOCM patients undergoing ASA with a low-dose (1.0-1.9 mL) or a high-dose (2.0-3.8 mL) of alcohol had similar short-and long-term outcomes. A higher rate of repeated septal reduction procedures was observed in the group treated with a low-dose of alcohol.
PrintDisplayed: 15/8/2024 16:32